Dean F Bajorin

22PUBLICATIONS
189CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer cell biologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 07, 2025
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.

Matthew D Galsky, Dean F Bajorin, Yoshihiko Tomita

|Oct 11, 2024
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.

Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend

|Jul 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease.

Jack P Gleeson, Andrea Knezevic, Maria Bromberg

|May 01, 2024
Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.

Andrew T Lenis, Karissa Whiting, Vignesh Ravichandran

|Sep 08, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.

Brendan J Guercio, Michal Sarfaty, Min Yuen Teo

|Jan 05, 2023
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.

Jonathan A Coleman, Wesley Yip, Nathan C Wong

Pageof 4

Frequent Collaborators

10 joint publications

Jonathan E Rosenberg

10 joint publications

Hikmat Al-Ahmadie

10 joint publications

Samuel Funt

8 joint publications

Gopa Iyer